A clinical study in metastatic colorectal cancer (CRC) patients demonstrated significantly higher tumour MRP2 expression in non-responders to oxaliplatin-based combination chemotherapy, correlating to elevated ABCC2 mRNA with reduced intracellular drug accumulation and oxaliplatin resistance [42]. Here, ABCC2 is linked to neoplasm.